Bodet Milin, C.
22  results:
Search for persons X
?
2

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
3

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
5

Standardization of 18F-FDG-PET/CT According to Deauville Cr..:

Zamagni, E ; Nanni, C ; Dozza, L...
Zamagni , E , Nanni , C , Dozza , L , Carlier , T , Bailly , C , Tacchetti , P , Versari , A , Chauvie , S , Gallamini , A , Gamberi , B , Caillot , D , Patriarca , F , Macro , M , Boccadoro , M , Garderet , L , Barbato , S , De Fanti , S , Perrot , A , Gay , F , Sonneveld , P , Karlin , L , Cavo , M , Bodet-Milin , C , Moreau , P & Kraeber-Bodéré , F 2021 , ' Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma ' , Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol. 39 , no. 2 , pp. 116-125 . https://doi.org/10.1200/jco.20.00386.  , 2021
 
?
6

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
7

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
8

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
9

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
10

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
11

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
12

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
13

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
14

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
?
15

Obinutuzumab versus Rituximab in young patients with advanc..:

Le Gouill, Steven ; Ghesquieres, Hervé ; Obéric, Lucie...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2020008750.  , 2021
 
1-15